246 related articles for article (PubMed ID: 30232801)
1. [Meningeal syndrome in a patient treated with a combination of immune checkpoint inhibitors for a metastatic melanoma].
Bello-Chavolla OY; Cortes-Arroyo JE; Vargas-Vazquez A; Quiroz-Compean F; Leal-Gutierrez G; Barragan-Dessavre M; Martinez-Samano JE
Rev Neurol; 2018 Oct; 67(7):279-280. PubMed ID: 30232801
[TBL] [Abstract][Full Text] [Related]
2. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.
Hantel A; Gabster B; Cheng JX; Golomb H; Gajewski TF
J Immunother Cancer; 2018 Jul; 6(1):73. PubMed ID: 30012206
[TBL] [Abstract][Full Text] [Related]
3. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.
Chin CK; Hall S; Green C; Van Hazel G; Spagnolo D; Cheah CY
Eur J Cancer; 2019 Jul; 115():84-87. PubMed ID: 31129384
[No Abstract] [Full Text] [Related]
4. Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma.
Lasocki A; Smith K
J Clin Neurosci; 2020 Apr; 74():240-241. PubMed ID: 31983645
[TBL] [Abstract][Full Text] [Related]
5. Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab.
Omodaka T; Kiniwa Y; Sato Y; Suwa M; Sato M; Yamaguchi T; Sato A; Miyake T; Okuyama R
J Dermatol; 2018 Oct; 45(10):e289-e290. PubMed ID: 29667767
[No Abstract] [Full Text] [Related]
6. Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.
Saibil SD; Bonilla L; Majeed H; Sotov V; Hogg D; Chappell MA; Cybulsky M; Butler MO
Curr Oncol; 2019 Jun; 26(3):e418-e421. PubMed ID: 31285688
[TBL] [Abstract][Full Text] [Related]
7. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
Alnabulsi R; Hussain A; DeAngelis D
Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409
[TBL] [Abstract][Full Text] [Related]
8. Case Report: A Variety of Immune-Related Adverse Events Triggered by Immune Checkpoint Inhibitors in a Subject With Malignant Melanoma: Destructive Thyroiditis, Aseptic Meningitis and Isolated ACTH Deficiency.
Katakura Y; Kimura T; Kusano T; Tatsumi F; Iwamoto Y; Sanada J; Fushimi Y; Shimoda M; Kohara K; Nakanishi S; Kaku K; Mune T; Kaneto H
Front Endocrinol (Lausanne); 2021; 12():722586. PubMed ID: 34712202
[TBL] [Abstract][Full Text] [Related]
9. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.
Kuwatsuka Y; Iwanaga A; Kuwatsuka S; Okubo Y; Murayama N; Ishii N; Hashimoto T; Utani A
J Dermatol; 2018 Jan; 45(1):e21-e22. PubMed ID: 28944534
[No Abstract] [Full Text] [Related]
10. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
Tan I; Malinzak M; Salama AKS
J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
[TBL] [Abstract][Full Text] [Related]
11. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma.
Gao CA; Weber UM; Peixoto AJ; Weiss SA
J Immunother Cancer; 2019 Oct; 7(1):262. PubMed ID: 31623673
[TBL] [Abstract][Full Text] [Related]
12. A case of aseptic meningitis without neck rigidity occurring in a metastatic melanoma patient treated with ipilimumab.
Oishi K; Nakao M; Maeda S; Matsushita T; Ikeda T; Yamada T; Takehara K; Hamaguchi Y
Eur J Dermatol; 2017 Apr; 27(2):193-194. PubMed ID: 28007669
[No Abstract] [Full Text] [Related]
13. Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy.
Irwin DE; Davis B; Bell JA; Galaznik A; Garcia-Ribas I
J Comp Eff Res; 2019 Jan; 8(2):81-90. PubMed ID: 30547675
[TBL] [Abstract][Full Text] [Related]
14. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
[TBL] [Abstract][Full Text] [Related]
15. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab.
Page B; Borradori L; Beltraminelli H; Yawalkar N; Hunger RE
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e256-e257. PubMed ID: 28430376
[No Abstract] [Full Text] [Related]
16. Bilateral anterior uveitis and unilateral facial palsy due to ipilimumab for metastatic melanoma in an individual with human leukocyte antigen DR4: A case report.
Numata S; Iwata Y; Okumura R; Arima M; Kobayashi T; Watanabe S; Suzuki K; Horiguchi M; Sugiura K
J Dermatol; 2018 Jan; 45(1):113-114. PubMed ID: 28225147
[No Abstract] [Full Text] [Related]
17. Case 9-2020: A 64-Year-Old Man with Shortness of Breath, Cough, and Hypoxemia.
Reynolds KL; Sullivan RJ; Fintelmann FJ; Mansour MK; England J
N Engl J Med; 2020 Mar; 382(12):1150-1159. PubMed ID: 32187473
[No Abstract] [Full Text] [Related]
18. Dual checkpoint inhibitor-associated eosinophilic enteritis.
Yang J; Lagana SM; Saenger YM; Carvajal RD
J Immunother Cancer; 2019 Nov; 7(1):310. PubMed ID: 31730503
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint Inhibitor-Associated Hypophysitis.
Chang LS; Yialamas MA
J Gen Intern Med; 2018 Jan; 33(1):125-127. PubMed ID: 28770379
[No Abstract] [Full Text] [Related]
20. Development of Poliosis Following Checkpoint Inhibitor Treatment for Cutaneous Melanoma.
Ediriwickrema LS; Liu CY; Kikkawa DO; Korn BS
Ophthalmic Plast Reconstr Surg; 2019; 35(5):e121-e122. PubMed ID: 31373986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
